SPIRIT PRIME Clinical Trial

Trial Profile

SPIRIT PRIME Clinical Trial

Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT PRIME
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Nov 2011 Primary endpoint 'Target-lesion-failure-rate' has been met.
    • 02 Nov 2011 Planned End Date changed to 30 Apr 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top